··*Emailhjie2005@aliyun.com———沈皆亮郝杰*400016R681A1006-7108201407-0844-05、、。。。Advancesinthetreatmentofosteoporosis———newtargetsandnewdrugsSHENJieliangHAOJieDepartmentofOrthopedicstheFirstAffiliatedHospitalofChongqingMedicalUniversityChongqing400016ChinaCorrespondingauthorHAOJieEmailhjie2005@aliyun.comAbstractOsteoporosisisasystemicmetabolicbonediseaseandhasgraduallybecomeaglobalpublichealthproblemduetoitshighincidencemorbidityandmortality.Recentlymanyeffortshavebeentriedtofindmoreefficientandsafermethodsforanti-osteoporosistreatment.Alongwiththefurtherunderstandingintobonemetabolismandbiologyseveralnovelosteoporosistargetsanddrugshavebeendevelopedwhichhaveopenedupafavorablenewsituationforthetreatmentofosteoporosis.Thispaperreviewstheadvancesinthetreatmentofosteoporosis.KeywordsOsteoporosisDrugsBonemetabolismTargetosteoporosisOP。1994WHO1。2001NIH2。。70%。XDXA。WHO、11~2.52.5。1。11.1。receptoractivatorofnuclearfactor-ΚBligandRANKLT1nuclearfactorofactivatedTcell1NFATC13。OPG4。RANKRANKLRANKLRANK。OPGRANKRANKLOPG44820147207ChinJOsteoporosJuly2014Vol20No.7Publishedonline.wanfangdate.com.cndoi10.3969/j.issn.1006-7108.2014.07.026RANKLRANK。src。Src5。src6。。KcathepsinK7。K8。1TilmanDRachnerLacent2011Fig.1OsteoclastphysiologyandpotentialtherapeutictargetsquotedfromTilamnDRachnerLacent20111.2。D。I、、。D、9。。CaSR。CaSRPTH。CaSR、CaSR。。CaSR10。CaSRG1993Brown。Wnt/β-catenin11。Wntdickkopf-1Dkk-1sclerostin。1.3Semaphorin-3AHayashi———Semaphorin-3A12。54820147207ChinJOsteoporosJuly2014Vol20No.72TilmanDRachnerLacent2011Fig.2OsteoblastphysiologyandpotentialtherapeutictargetsquotedfromTilmanDRachnerLancet2011Semaphorin-3A。Semaphorin-3A-1neuropilin-1ITAMRhoARANKLWnt/β-。1.4Sjogren13。TNFCD4+TCD11b+/GR1。Cho14。22.12.1.1DenosumabRANKL。15。213FREEDOM163。10。。FREEDOM177808≥75/T-score≤-2.5。。。。2.1.2OdanacatibK。K。2Ⅱ18Eisman1920111。50mg132。BALP。K64820147207ChinJOsteoporosJuly2014Vol20No.7Eastell20ONO-5334、ONO-533412。K。。2.1.3Saracatinibsrc。59I21ICCTXIN25d88%67%。30%VS6%24%VS0%。2.22.2.1MK-5442、PTH。PTHPTH22。2.2.2AMG7852011AMG78523。、、、7285d。。5%3%。AMG785。6AMG785。。Ⅱ。。15Table1FivenoveldrugsforosteoprosistherapyRANKRANKIIIKKIIIsrcsrcIIMK-5442IIAMG785II3。。。【】1KanisJAMeltonLJ3rdChristiansenCetal.Thediagnosisofosteoporosis.JournalofBoneandMineralResearch1994981137-1141.2NihD.Consensusdevelopmentpanelonosteoporosispreventiondiagnosisandtherapy.JAMA20012856785-795.3TakayanagiHOgasawaraKHidaSetal.T-cell-mediatedregulationofosteoclastogenesisbysignallingcross-talkbetweenRANKLandIFN-gamma.Nature20004086812600-605.4TokudaHKannoYIshisakiAetal.InterleukinIL-17enhancestumornecrosisfactor-alpha-stimulatedIL-6synthesisviap38mitogen-activatedproteinkinaseinosteoblasts.JournalofCellularBiochemistry20049151053-1061.5SorianoPMontgomeryCGeskeRetal.Targeteddisruptionofthec-srcproto-oncogeneleadstoosteopetrosisinmice.Cell1991644693-702.6MarziaMSimsNAVoitSetal.Decreasedc-Srcexpressionenhancesosteoblastdifferentiationandbonefrmation.TheJournalofCellBiology20001512311-320.74820147207ChinJOsteoporosJuly2014Vol20No.77GarneroPFerrerasMKarsdalMAetal.ThetypeIcollagenfragmentsICTPandCTXrevealdistinctenzymaticpathwaysofbonecollagendegradation.JournalofBoneandMineralResearch2003185859-867.8LecailleFKaletaJBrommeD.Humanandparasiticpapain-likecysteineproteasestheirroleinphysiogyandpathologyandrecentdevelopmentsininhibitordesign.ChemicalReviews2002102124459-4488.9ChangWTuCPrattSetal.ExtracellularCa2+-sensingreceptorsmodulatematrixproductionandmineralizationinchondrogenicRCJ3.1C5.18cells.Endocrinology200214341467-1474.10HouseMGKohlmeierLChattopadhyayNetal.Expressionofanextracellularcalcium-sensingreceptorinhumanandmousebonemarrowcells.JournalofBoneandMineralResearch199712121959-1970.11BaronRRawadiG.TargetingtheWnt/beta-cateninpathwaytoregulateboneformationintheadultskeleton.Endocrinology200714862635-2643.12HayashiMNakashimaTTaniguchiMetal.Osteoprotectionbysemaphorin3A.Nature2012485739669-74.13SjogrenKEngdahlCHenningetal.Thegutmicrobiotaregulatesbonemassinmice.JournalofBoneandMineralResearch20122761357-1367.14ChoIYamanishiSCoxLetal.Antibioticsinearlylifealterthemurinecolonicmicrobiomeandadiposity.Nature20124887413621-626.15EastellRChristiansenCGrauerAetal.Effectsofdenosumabonboneturnovermarkersinpostmenopausalosteoporosis.JournalofBoneandMineralResearch2011263530-537.16CummingsSRSanMartinJMcClungMRetal.Denosumabforpreventionoffracturesinpostmenopausalwomenwithosteoporosis.TheNewEnglandJournalofMedicine20093618756-765.17BoonenSAdachiJDManZetal.Treatmentwithdenosumabreducestheincidenceofnewvertebralandhipfracturesinpostmenopausalwomenathighrisk.TheJournalofClinicalEndocrinologyandMetabolism20119661727-1736.18BoneHGBologneseMAYuenCKetal.Effectsofdenosumabtreatmentanddiscontinuationonbonemineraldensityandboneturnovermarkersinpostmenopausalwomenwithlowbonemass.TheJournalofClinicalEndocrinologyandMetabolism2011964972-980.19EismanJABoneHGHoskingDJetal.Odanacatibinthetreatmentofpostmenopausalwomenwithlowbonemineraldensitythree-yearcontinuedtherapyandresolutionofeffect.JournalofBoneandMineralResearch2011262242-251.20Eas